Advanced Filters
noise

Heerlen, Netherlands Clinical Trials

A listing of Heerlen, Netherlands clinical trials actively recruiting patients volunteers.

Found 102 clinical trials

Prospective Bladder Cancer Infrastructure (ProBCI)

Prospective nation-wide cohort of high-risk non-muscle-invasive, muscle-invasive and metastatic bladder cancer in the Netherlands

18 years of age All Phase N/A

Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

This is a registry study in adult patients with newly diagnosed or refractory/relapsed acute myeloid leukemia. Investigator's sites: 51 sites in Germany. Primary objectives: Identification of epidemiological data on AML: age, prognostic factors and subgroup distributions. Incidence and age distribution are compared with the data of population-related tumor registry. Evaluation …

18 years of age All Phase N/A
A Anne Dutour, Prof, MD

CARdiomyopathy in Type 2 DIAbetes Mellitus

The objective of the CARDIATEAM clinical study is to assess the uniqueness of diabetic cardiomyopathy (DCM) relative to other forms of cardiomyopathy using unsupervised clustering approaches based on deep phenotyping (clinical, imaging and biological) information.

40 - 80 years of age All Phase N/A

CytOSorb TreatMent Of Critically Ill PatientS Registry

Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care

years of age All Phase N/A
K Kristel Muijs

Prediction Models for Complications After CRT in Esophageal Cancer

The aim of this project is to develop and validate NTCP-models for complications after nCRT (and surgical resection), that can be uses for model-based dose optimization for PhRT and PRT, and for model-based selection for PRT, in patients with esophageal cancer

18 - 100 years of age All Phase N/A
D Domenico Baccellieri, MD

European Venous Registry

The European Venous Registry (EVeR) is an international repository of data on the treatments and outcomes of people with deep venous disease. The registry is designed to evaluate the outcomes of venous interventions over a ten-year period, with the ultimate goal to inform clinical decision making through the delivery of …

18 years of age All Phase N/A

Promoting Optimal Treatment Choices in Neonates With Suspected Early-Onset Sepsis

In this study, three neonatal evidence-based antibiotic stewardship strategies will be implemented in Dutch hospitals. These include the early-onset sepsis (EOS) calculator, procalcitonin (PCT)-guided therapy, and IV-to-oral switch therapy. These strategies have been proven to be effective and safe and are already applied in several Dutch hospitals. However, this is …

- 3 years of age All Phase N/A

Translational Investigation of the Glutamatergic and GABAergic System in Schizophrenia

In the last years, the imbalance between excitatory and inhibitory neuronal activity has come to the fore as a possible molecular disease mechanism of schizophrenia . Pharmacological studies have suggested different fMRI and EEG markers of that molecular dysfunction (resting state connectivity changes, auditory mismatch and steady state deficits). However, …

18 - 80 years of age All Phase N/A
R Robert Jan M van Geuns, Prof. dr.

South East (Zuid Oost) Netherlands Heart Registry

Rationale: Patients undergoing percutaneous coronary intervention (PCI) for chronic coronary syndrome (CCS) or acute coronary syndrome (ACS) have a residual risk of ischemic events after PCI due to the progression of atherosclerosis in and outside the stented segments. The residual risk is affected by thrombotic, lipid, inflammation and diabetic risk …

years of age All Phase N/A
O Oleg Gluz, PD. Dr. med.

PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS

There is only limited data for premenopausal patients in general, as well as for differences in the use of OFS in the subgroups of pre- and perimenopausal patients, respectively. The WSG ADAPT trial data on the impact of postmenopausal status and/or use of OFS within 3-4 weeks endocrine induction therapy …

18 - 60 years of age Female Phase N/A

Simplify language using AI